Jeffrey Simmons compensation by year
Elanco Animal Health Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $688,118 | $775,185 | $1,000,000 | $1,025,000 | $1,046,000 | $1,125,000 | $1,200,000 | $1,200,000 | $1,200,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $0 |
| Stock awards | $2,400,000 | $2,530,654 | $13,534,347 | $6,860,048 | $9,261,019 | $7,650,029 | $8,400,005 | $9,000,027 | $9,000,000 |
| Option awards | $0 | $1,119,445 | $0 | $0 | $0 | $2,550,002 | $2,800,003 | $3,000,005 | $3,000,004 |
| Non-equity incentive | $379,841 | $907,450 | $1,248,000 | $1,045,500 | $1,725,900 | $1,360,125 | $1,232,400 | $1,606,800 | $1,700,400 |
| Pension and deferred compensation | $1,261,845 | $0 | $0 | $0 | $0 | $0 | — | — | $0 |
| All other | $41,287 | $46,511 | $19,422 | $28,272 | $27,096 | $28,476 | $30,761 | $26,871 | $25,352 |
| Total | $4,771,091 | $5,379,245 | $15,801,769 | $8,958,820 | $12,060,015 | $12,713,632 | $13,663,169 | $14,833,704 | $14,925,756 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elanco Animal Health Inc DEF 14A filed April 8, 2026, accession 0001739104-26-000016, and prior-year filings.
How this page was built: the Elanco Animal Health Inc filed document, accession 0001739104-26-000016. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 530,504 | $12,005,306 | — |
| RSU | 374,299 | $8,470,386 | — |
| RSU | 265,252 | $6,002,653 | — |
| RSU | 125,391 | $2,837,598 | — |
| RSU | 84,548 | $1,913,321 | — |
| Option | 273,470 | — | $16.03 |
| Option | 556,587 | — | $11.31 |
| Option | 193,104 | — | $11.26 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Elanco Animal Health Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
16 Form 4 lines since the FY2025 proxy (filed April 8, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-30 | Grant or award derivative | — | 122.59 | $23.06 | 25,741.91 |
| 2026-10-16 | Grant or award derivative | — | 120.04 | $23.55 | 25,619.32 |
| 2026-10-02 | Grant or award derivative | — | 127.68 | $22.14 | 25,499.28 |
| 2026-09-18 | Grant or award derivative | — | 126.09 | $22.42 | 25,371.6 |
| 2026-09-04 | Grant or award derivative | — | 115.38 | $24.50 | 25,245.51 |
| 2026-08-21 | Grant or award derivative | — | 117.94 | $23.97 | 25,130.12 |
| 2026-08-07 | Grant or award derivative | — | 127.8 | $22.12 | 25,012.19 |
| 2026-07-24 | Grant or award derivative | — | 113.49 | $24.91 | 24,884.39 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Elanco Animal Health discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $5,520,000 | $41,867,307 | $44,498 | $47,431,804 |
| Involuntary termination without cause | $5,520,000 | $0 | $57,126 | $5,577,126 |
| Disability | $5,520,000 | $23,332,241 | $57,126 | $28,909,367 |
Per the Potential Payments Upon Termination or Change in Control table in Elanco Animal Health Inc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Elanco Animal Health’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jeffrey Simmons · this page | President and CEO | $14,925,756 |
| Todd Young | Former Executive Vice President and Chief Financial Officer | $4,754,889 |
| Robert VanHimbergen | Executive Vice President and Chief Financial Officer | $4,661,304 |
| Ellen de Brabander | Executive Vice President, Innovation and Regulatory | $3,911,229 |
| Ramiro Cabral | Executive Vice President, President International | $3,243,767 |
| Timothy Bettington | Executive Vice President, Center for Strategic Growth | $2,583,505 |
Board service
Elanco Animal Health board · FY2021–FY2025How this board is paid
Company policy: Elanco Animal Health pays directors a $90,000 cash retainer and $240,000 in DSUs. As stated in Elanco Animal Health's FY2025 proxy.
Committees
Finance, Strategy and Oversight
The full Elanco Animal Health compensation record
free company briefThis page is one person within Elanco Animal Health's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Elanco Animal Health proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Elanco Animal Health's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elanco Animal Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.